VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Gentium S.p.A. (Nasdaq: GENT) announced today the completion of patient enrollment in a Phase II/III European, multi-center, open label, randomized trial to evaluate the prophylactic use of Defibrotide in pediatric patients undergoing stem cell transplantation who are at high risk for hepatic veno-occlusive disease (VOD).
